Celldex Therapeutics (CLDX) Common Equity (2010 - 2026)

Celldex Therapeutics' Common Equity history runs 17 years deep, the most recent figure standing at $456.2 million for Q1 2026.

• On a quarterly basis, Common Equity fell 35.1% year-over-year to $456.2 million in Q1 2026; TTM through Mar 2026 was $456.2 million, a 35.1% decrease from a year earlier, with the FY2025 full-year figure at $527.2 million, down 29.43% from the prior year.
• Common Equity fell to $456.2 million in Q1 2026 per CLDX's latest filing, from $527.2 million in the prior quarter.
• Across five years, Common Equity topped out at $838.6 million in Q1 2024 and bottomed at $246.7 million in Q3 2023.
• The 5-year median for Common Equity is $456.2 million (2026), against an average of $518.6 million.
• Across the five-year window, Common Equity jumped 218.54% in 2024 and plunged 35.1% in 2026, its largest moves.
• Year by year, Common Equity stood at $326.2 million in 2022, then surged by 31.57% to $429.2 million in 2023, then jumped by 74.06% to $747.0 million in 2024, then declined by 29.43% to $527.2 million in 2025, then retreated by 13.46% to $456.2 million in 2026.
• Per Business Quant, the three latest CLDX Common Equity figures stand at $456.2 million (Q1 2026), $527.2 million (Q4 2025), and $598.4 million (Q3 2025).